Actively Recruiting
Safety Study of Mavacamten in Korean Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Led by Bristol-Myers Squibb · Updated on 2024-11-06
600
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting an observational post-marketing surveillance study to evaluate the real-world safety of mavacamten in adult patients with symptomatic obstructive hypertrophic cardiomyopathy oHCM in Korea. The study focuses on adults who are prescribed mavacamten for this condition and aims to monitor adverse events associated with the treatment. Participants will receive mavacamten according to the approved product label. This study enrolls individuals who have been prescribed mavacamten and will track their treatment over time without altering their prescribed care. During the study, researchers will monitor participants for up to 12 months to record any adverse events experienced. Data on safety will be collected through regular assessments, and participants will be observed in their usual care settings. The total duration of follow-up is up to one year after starting mavacamten treatment.
CONDITIONS
Brief Title
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Research Team
B
BMS Study Connect Contact Center www.BMSStudyConnect.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here